Hints and tips:
...Under 28 U.S.C. section 1408, a company can file bankruptcy in any district where it has its domicile, principal place of business, or principal assets for 180 days prior to bankruptcy....
...Sure, a CCC-rated PIK bond looks better than a defaulted bond in your portfolio. But, as S&P puts it when explaining why U.S....
...ArtFi 2024-1’s prospectus has further detail on the collateral backing the deal, which it notes can include “fine art, collectibles, design furniture, coins, books, jewelry, watches, wine or other spirits...
...In last night from the SEC: The Securities and Exchange Commission today [Thursday] announced that Skechers U.S.A....
...Biotech business Redx Pharma this week blamed low liquidity on London’s junior market for its decision to delist its shares from Aim and re-register as a private company....
...But some investors believe selling discipline against a shot is a losing game when big pharma companies are competing to meet the demands of the one in eight people worldwide who are classed as obese....
...The slower expectations for the transition come as companies make U-turns on their climate pledges and governments double down on fossil fuels amid energy security concerns....
...Here’s a chart looking at the waning outperformance of all 39 different categories that S&P DJI tracks — across both equities and fixed income....
...The U-turn puts S&P at odds with debt rating rival Moody’s, which still rates ESG criteria on a one to five scale. S&P is influential, with debt ratings that can affect a company’s borrowing cost....
...In a quieter deal environment, this deal underscores that Big Pharma has the means to make big bets....
...The price has been pushed up by F1’s booming popularity in the US, and also the sport’s new spending caps that have put a lid on costs....
...(when the U.S....
...An investor opposed to the deal, Energy Income Partners, pointed out that this position was a U-turn from a bullish management outlook offered as recently as 2022....
...including a senior member of Astellas Pharma; levied a record fine against Deloitte, and amended its espionage law to cover ordinary business activities....
...s=46&t=uS_p1jt3N5TYYYWqkDeEiw Also 15 November 2022: “Bnk To The Future (the ‘Company’) announces that its previously announced non-binding letter of intent with SALT Blockchain, Inc....
...Swiss pharma group Novartis plans to spin off its generic drugs business after a lengthy review of the division, which drew interest from private equity firms and even calls from politicians for it to be...
...The Renaissance Capital IPO Index, which tracks issues for two years after listing, is down 54 per cent over the past 12 months, far worse that the S&P 500 index....
...Here’s our best attempt at taking a photo of the phone: OK, the Waystar Corp. of S1E3 now seems to be Waystar Royco Inc/WAY:NYSE, which plausibly could be a security representing a different class of shares...
...A modest proposal for Goldman Goldman Sachs partners are meeting in Florida this week after a difficult stretch, with 3,000 lay-offs, falling profits and a big strategy U-turn by chief executive David Solomon...
...The rating agency maintained the UK’s AA- investment grade but warned that the outlook was now negative rather than stable, mirroring the action taken last week by its peer S&P....
...Here’s a thing that’s happening: Aug 11 (WSJ) - The U.S....
...From Bloomberg on Friday: Affirm, the leading U.S....
...$41.1m, according to S&P Capital IQ....
...A Unilever buyout would be one of the largest ever on the London market, bringing together the FTSE 100’s third-largest company with a division that, if independent, would be in its top 20....
...McKinsey: data deception Kevin Sneader was probably already having a long week when he received the call from S&P Global chief executive Doug Peterson earlier this year....
International Edition